nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.094	0.201	CbGbCtD
Trametinib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0877	0.188	CbGbCtD
Trametinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0713	0.153	CbGbCtD
Trametinib—CYP3A4—Betamethasone—psoriatic arthritis	0.0611	0.131	CbGbCtD
Trametinib—CYP3A4—Prednisolone—psoriatic arthritis	0.0603	0.129	CbGbCtD
Trametinib—CYP3A4—Prednisone—psoriatic arthritis	0.057	0.122	CbGbCtD
Trametinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.0356	0.0762	CbGbCtD
Trametinib—MAP2K2—IL-1 signaling pathway—REL—psoriatic arthritis	0.00392	0.0333	CbGpPWpGaD
Trametinib—MAP2K1—IL-1 signaling pathway—REL—psoriatic arthritis	0.00367	0.0311	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.0032	0.0272	CbGpPWpGaD
Trametinib—MAP2K2—Leptin signaling pathway—REL—psoriatic arthritis	0.00306	0.026	CbGpPWpGaD
Trametinib—MAP2K1—Leptin signaling pathway—REL—psoriatic arthritis	0.00286	0.0243	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—REL—psoriatic arthritis	0.00264	0.0225	CbGpPWpGaD
Trametinib—MAP2K2—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.00261	0.0222	CbGpPWpGaD
Trametinib—MAP2K2—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.00249	0.0211	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—REL—psoriatic arthritis	0.00247	0.021	CbGpPWpGaD
Trametinib—MAP2K1—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.00245	0.0208	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.00233	0.0198	CbGpPWpGaD
Trametinib—MAP2K2—IL-6 signaling pathway—CRP—psoriatic arthritis	0.0023	0.0195	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.00222	0.0189	CbGpPWpGaD
Trametinib—MAP2K1—IL-6 signaling pathway—CRP—psoriatic arthritis	0.00215	0.0182	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.00208	0.0177	CbGpPWpGaD
Trametinib—MAP2K2—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.00207	0.0176	CbGpPWpGaD
Trametinib—MAP2K1—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.00194	0.0164	CbGpPWpGaD
Trametinib—MAP2K2—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00187	0.0159	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.00187	0.0159	CbGpPWpGaD
Trametinib—MAP2K2—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00185	0.0158	CbGpPWpGaD
Trametinib—MAP2K2—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.00182	0.0155	CbGpPWpGaD
Trametinib—MAP2K2—Cellular roles of Anthrax toxin—TNF—psoriatic arthritis	0.00178	0.0151	CbGpPWpGaD
Trametinib—MAP2K2—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.00176	0.0149	CbGpPWpGaD
Trametinib—MAP2K1—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00175	0.0149	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.00175	0.0149	CbGpPWpGaD
Trametinib—MAP2K1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00174	0.0147	CbGpPWpGaD
Trametinib—MAP2K2—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00173	0.0147	CbGpPWpGaD
Trametinib—MAP2K1—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.0017	0.0145	CbGpPWpGaD
Trametinib—MAP2K1—Cellular roles of Anthrax toxin—TNF—psoriatic arthritis	0.00166	0.0141	CbGpPWpGaD
Trametinib—MAP2K2—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00166	0.0141	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.00164	0.014	CbGpPWpGaD
Trametinib—MAP2K1—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00162	0.0137	CbGpPWpGaD
Trametinib—MAP2K1—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00155	0.0132	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00155	0.0131	CbGpPWpGaD
Trametinib—MAP2K2—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00149	0.0127	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.00146	0.0124	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00145	0.0123	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HLA-C—psoriatic arthritis	0.00142	0.012	CbGpPWpGaD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.0014	0.0119	CbGpPWpGaD
Trametinib—MAP2K1—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00139	0.0118	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.00139	0.0118	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.00137	0.0116	CbGpPWpGaD
Trametinib—Melaena—Methotrexate—psoriatic arthritis	0.00136	0.00328	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.00135	0.00325	CcSEcCtD
Trametinib—Cardiac failure congestive—Prednisone—psoriatic arthritis	0.00134	0.00322	CcSEcCtD
Trametinib—MAP2K1—DAP12 interactions—HLA-C—psoriatic arthritis	0.00132	0.0113	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.00131	0.0111	CbGpPWpGaD
Trametinib—Pancreatitis—Triamcinolone—psoriatic arthritis	0.0013	0.00313	CcSEcCtD
Trametinib—Pancreatitis—Methylprednisolone—psoriatic arthritis	0.0013	0.00312	CcSEcCtD
Trametinib—Dry skin—Betamethasone—psoriatic arthritis	0.00128	0.00307	CcSEcCtD
Trametinib—Dry skin—Dexamethasone—psoriatic arthritis	0.00128	0.00307	CcSEcCtD
Trametinib—Hypokalaemia—Betamethasone—psoriatic arthritis	0.00127	0.00305	CcSEcCtD
Trametinib—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.00127	0.00305	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—psoriatic arthritis	0.00126	0.00304	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—psoriatic arthritis	0.00126	0.00304	CcSEcCtD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.00125	0.0106	CbGpPWpGaD
Trametinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00118	0.00284	CcSEcCtD
Trametinib—Infestation—Methylprednisolone—psoriatic arthritis	0.00118	0.00284	CcSEcCtD
Trametinib—Bradycardia—Prednisolone—psoriatic arthritis	0.00117	0.00283	CcSEcCtD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.00117	0.00993	CbGpPWpGaD
Trametinib—Haemoglobin—Prednisolone—psoriatic arthritis	0.00116	0.00279	CcSEcCtD
Trametinib—Haemorrhage—Prednisolone—psoriatic arthritis	0.00115	0.00278	CcSEcCtD
Trametinib—MAP2K2—Amyotrophic lateral sclerosis (ALS)—TNF—psoriatic arthritis	0.00115	0.00974	CbGpPWpGaD
Trametinib—Epistaxis—Triamcinolone—psoriatic arthritis	0.00112	0.00269	CcSEcCtD
Trametinib—Dry skin—Prednisone—psoriatic arthritis	0.00111	0.00268	CcSEcCtD
Trametinib—Hypokalaemia—Prednisone—psoriatic arthritis	0.0011	0.00266	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—psoriatic arthritis	0.0011	0.00264	CcSEcCtD
Trametinib—Hyperglycaemia—Dexamethasone—psoriatic arthritis	0.00109	0.00261	CcSEcCtD
Trametinib—Hyperglycaemia—Betamethasone—psoriatic arthritis	0.00109	0.00261	CcSEcCtD
Trametinib—Bradycardia—Triamcinolone—psoriatic arthritis	0.00108	0.0026	CcSEcCtD
Trametinib—Bradycardia—Methylprednisolone—psoriatic arthritis	0.00108	0.0026	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—MEFV—psoriatic arthritis	0.00107	0.00913	CbGpPWpGaD
Trametinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.00107	0.00257	CcSEcCtD
Trametinib—Haemoglobin—Triamcinolone—psoriatic arthritis	0.00107	0.00257	CcSEcCtD
Trametinib—Haemoglobin—Methylprednisolone—psoriatic arthritis	0.00106	0.00256	CcSEcCtD
Trametinib—Haemorrhage—Triamcinolone—psoriatic arthritis	0.00106	0.00256	CcSEcCtD
Trametinib—Haemorrhage—Methylprednisolone—psoriatic arthritis	0.00106	0.00255	CcSEcCtD
Trametinib—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.00104	0.00251	CcSEcCtD
Trametinib—Arrhythmia—Prednisolone—psoriatic arthritis	0.00103	0.00248	CcSEcCtD
Trametinib—Pancreatitis—Prednisone—psoriatic arthritis	0.00103	0.00247	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—MEFV—psoriatic arthritis	0.00101	0.00854	CbGpPWpGaD
Trametinib—Erythema—Prednisolone—psoriatic arthritis	0.001	0.00242	CcSEcCtD
Trametinib—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00099	0.00238	CcSEcCtD
Trametinib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000983	0.00237	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000981	0.00833	CbGpPWpGaD
Trametinib—Bradycardia—Betamethasone—psoriatic arthritis	0.00098	0.00236	CcSEcCtD
Trametinib—Bradycardia—Dexamethasone—psoriatic arthritis	0.00098	0.00236	CcSEcCtD
Trametinib—Neutropenia—Prednisone—psoriatic arthritis	0.00098	0.00236	CcSEcCtD
Trametinib—Haemoglobin—Betamethasone—psoriatic arthritis	0.000968	0.00233	CcSEcCtD
Trametinib—Haemoglobin—Dexamethasone—psoriatic arthritis	0.000968	0.00233	CcSEcCtD
Trametinib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000963	0.00232	CcSEcCtD
Trametinib—Haemorrhage—Betamethasone—psoriatic arthritis	0.000963	0.00232	CcSEcCtD
Trametinib—Angiopathy—Methylprednisolone—psoriatic arthritis	0.000961	0.00231	CcSEcCtD
Trametinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000954	0.0023	CcSEcCtD
Trametinib—MAP2K2—Ceramide signaling pathway—TNF—psoriatic arthritis	0.000951	0.00808	CbGpPWpGaD
Trametinib—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000948	0.00228	CcSEcCtD
Trametinib—Vision blurred—Prednisolone—psoriatic arthritis	0.000947	0.00228	CcSEcCtD
Trametinib—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000946	0.00228	CcSEcCtD
Trametinib—Hyperglycaemia—Prednisone—psoriatic arthritis	0.000945	0.00228	CcSEcCtD
Trametinib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.000928	0.00223	CcSEcCtD
Trametinib—Erythema—Triamcinolone—psoriatic arthritis	0.000924	0.00223	CcSEcCtD
Trametinib—Erythema—Methylprednisolone—psoriatic arthritis	0.000922	0.00222	CcSEcCtD
Trametinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000922	0.00222	CcSEcCtD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000921	0.00782	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000918	0.0078	CbGpPWpGaD
Trametinib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.000905	0.00218	CcSEcCtD
Trametinib—Eye disorder—Dexamethasone—psoriatic arthritis	0.0009	0.00217	CcSEcCtD
Trametinib—Eye disorder—Betamethasone—psoriatic arthritis	0.0009	0.00217	CcSEcCtD
Trametinib—Back pain—Triamcinolone—psoriatic arthritis	0.000894	0.00215	CcSEcCtD
Trametinib—MAP2K1—Ceramide signaling pathway—TNF—psoriatic arthritis	0.00089	0.00756	CbGpPWpGaD
Trametinib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000874	0.0021	CcSEcCtD
Trametinib—Angiopathy—Betamethasone—psoriatic arthritis	0.000874	0.0021	CcSEcCtD
Trametinib—Hypertension—Prednisolone—psoriatic arthritis	0.000867	0.00209	CcSEcCtD
Trametinib—Arrhythmia—Betamethasone—psoriatic arthritis	0.00086	0.00207	CcSEcCtD
Trametinib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00086	0.00207	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—psoriatic arthritis	0.000859	0.00207	CcSEcCtD
Trametinib—Bradycardia—Prednisone—psoriatic arthritis	0.000854	0.00206	CcSEcCtD
Trametinib—MAP2K2—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000853	0.00725	CbGpPWpGaD
Trametinib—Haemoglobin—Prednisone—psoriatic arthritis	0.000843	0.00203	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.000839	0.00202	CcSEcCtD
Trametinib—Haemorrhage—Prednisone—psoriatic arthritis	0.000839	0.00202	CcSEcCtD
Trametinib—Erythema—Dexamethasone—psoriatic arthritis	0.000838	0.00202	CcSEcCtD
Trametinib—Erythema—Betamethasone—psoriatic arthritis	0.000838	0.00202	CcSEcCtD
Trametinib—MAP2K2—DAP12 interactions—HLA-B—psoriatic arthritis	0.000837	0.00711	CbGpPWpGaD
Trametinib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000824	0.00198	CcSEcCtD
Trametinib—Oedema—Prednisolone—psoriatic arthritis	0.00082	0.00197	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—psoriatic arthritis	0.000819	0.00197	CcSEcCtD
Trametinib—Cough—Triamcinolone—psoriatic arthritis	0.000806	0.00194	CcSEcCtD
Trametinib—MAP2K1—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000798	0.00678	CbGpPWpGaD
Trametinib—Hypertension—Triamcinolone—psoriatic arthritis	0.000798	0.00192	CcSEcCtD
Trametinib—Hypertension—Methylprednisolone—psoriatic arthritis	0.000796	0.00192	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.000793	0.00191	CcSEcCtD
Trametinib—Myalgia—Triamcinolone—psoriatic arthritis	0.000787	0.00189	CcSEcCtD
Trametinib—Myalgia—Methylprednisolone—psoriatic arthritis	0.000785	0.00189	CcSEcCtD
Trametinib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000785	0.00189	CcSEcCtD
Trametinib—Eye disorder—Prednisone—psoriatic arthritis	0.000784	0.00189	CcSEcCtD
Trametinib—MAP2K1—DAP12 interactions—HLA-B—psoriatic arthritis	0.000783	0.00665	CbGpPWpGaD
Trametinib—Infestation—Methotrexate—psoriatic arthritis	0.000781	0.00188	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000781	0.00188	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000779	0.00188	CcSEcCtD
Trametinib—Dry mouth—Triamcinolone—psoriatic arthritis	0.000769	0.00185	CcSEcCtD
Trametinib—Renal failure—Methotrexate—psoriatic arthritis	0.000767	0.00185	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—psoriatic arthritis	0.000761	0.00183	CcSEcCtD
Trametinib—Angiopathy—Prednisone—psoriatic arthritis	0.000761	0.00183	CcSEcCtD
Trametinib—Oedema—Triamcinolone—psoriatic arthritis	0.000754	0.00182	CcSEcCtD
Trametinib—Arrhythmia—Prednisone—psoriatic arthritis	0.000749	0.0018	CcSEcCtD
Trametinib—Infection—Triamcinolone—psoriatic arthritis	0.000749	0.0018	CcSEcCtD
Trametinib—Infection—Methylprednisolone—psoriatic arthritis	0.000747	0.0018	CcSEcCtD
Trametinib—Haematuria—Methotrexate—psoriatic arthritis	0.000744	0.00179	CcSEcCtD
Trametinib—Insomnia—Prednisolone—psoriatic arthritis	0.000742	0.00179	CcSEcCtD
Trametinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000738	0.00178	CcSEcCtD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000737	0.00627	CbGpPWpGaD
Trametinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000736	0.00177	CcSEcCtD
Trametinib—Mental disorder—Prednisone—psoriatic arthritis	0.000735	0.00177	CcSEcCtD
Trametinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000731	0.00176	CcSEcCtD
Trametinib—Erythema—Prednisone—psoriatic arthritis	0.00073	0.00176	CcSEcCtD
Trametinib—Malnutrition—Prednisone—psoriatic arthritis	0.00073	0.00176	CcSEcCtD
Trametinib—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000729	0.00176	CcSEcCtD
Trametinib—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000727	0.00175	CcSEcCtD
Trametinib—Hypertension—Betamethasone—psoriatic arthritis	0.000724	0.00174	CcSEcCtD
Trametinib—Hypertension—Dexamethasone—psoriatic arthritis	0.000724	0.00174	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000721	0.00613	CbGpPWpGaD
Trametinib—Myalgia—Dexamethasone—psoriatic arthritis	0.000714	0.00172	CcSEcCtD
Trametinib—Myalgia—Betamethasone—psoriatic arthritis	0.000714	0.00172	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000704	0.0017	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000701	0.00169	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000692	0.00167	CcSEcCtD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.00069	0.00586	CbGpPWpGaD
Trametinib—Vision blurred—Prednisone—psoriatic arthritis	0.000688	0.00166	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000687	0.00165	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000687	0.00165	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000685	0.00165	CcSEcCtD
Trametinib—Oedema—Dexamethasone—psoriatic arthritis	0.000684	0.00165	CcSEcCtD
Trametinib—Oedema—Betamethasone—psoriatic arthritis	0.000684	0.00165	CcSEcCtD
Trametinib—Insomnia—Triamcinolone—psoriatic arthritis	0.000682	0.00164	CcSEcCtD
Trametinib—Insomnia—Methylprednisolone—psoriatic arthritis	0.00068	0.00164	CcSEcCtD
Trametinib—Infection—Dexamethasone—psoriatic arthritis	0.00068	0.00164	CcSEcCtD
Trametinib—Infection—Betamethasone—psoriatic arthritis	0.00068	0.00164	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000675	0.00573	CbGpPWpGaD
Trametinib—Anaemia—Prednisone—psoriatic arthritis	0.000675	0.00163	CcSEcCtD
Trametinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000671	0.00162	CcSEcCtD
Trametinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000671	0.00162	CcSEcCtD
Trametinib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00067	0.00161	CcSEcCtD
Trametinib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00067	0.00161	CcSEcCtD
Trametinib—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000661	0.00159	CcSEcCtD
Trametinib—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000661	0.00159	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—psoriatic arthritis	0.000655	0.00158	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00065	0.00157	CcSEcCtD
Trametinib—Fatigue—Triamcinolone—psoriatic arthritis	0.00065	0.00157	CcSEcCtD
Trametinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000649	0.00156	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—psoriatic arthritis	0.000636	0.00153	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000632	0.00152	CcSEcCtD
Trametinib—Hypertension—Prednisone—psoriatic arthritis	0.00063	0.00152	CcSEcCtD
Trametinib—Chills—Methotrexate—psoriatic arthritis	0.000629	0.00151	CcSEcCtD
Trametinib—MAP2K2—Immune System—MEFV—psoriatic arthritis	0.000626	0.00532	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000623	0.0015	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000623	0.0015	CcSEcCtD
Trametinib—Arthralgia—Prednisone—psoriatic arthritis	0.000622	0.0015	CcSEcCtD
Trametinib—Myalgia—Prednisone—psoriatic arthritis	0.000622	0.0015	CcSEcCtD
Trametinib—Insomnia—Dexamethasone—psoriatic arthritis	0.000619	0.00149	CcSEcCtD
Trametinib—Insomnia—Betamethasone—psoriatic arthritis	0.000619	0.00149	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000617	0.00149	CcSEcCtD
Trametinib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000615	0.00148	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—psoriatic arthritis	0.000614	0.00148	CcSEcCtD
Trametinib—Erythema—Methotrexate—psoriatic arthritis	0.00061	0.00147	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—psoriatic arthritis	0.00061	0.00147	CcSEcCtD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000608	0.00517	CbGpPWpGaD
Trametinib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000597	0.00144	CcSEcCtD
Trametinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000596	0.00144	CcSEcCtD
Trametinib—Oedema—Prednisone—psoriatic arthritis	0.000596	0.00143	CcSEcCtD
Trametinib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000595	0.00143	CcSEcCtD
Trametinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000595	0.00143	CcSEcCtD
Trametinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000595	0.00143	CcSEcCtD
Trametinib—Infection—Prednisone—psoriatic arthritis	0.000592	0.00143	CcSEcCtD
Trametinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000591	0.00142	CcSEcCtD
Trametinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000591	0.00142	CcSEcCtD
Trametinib—Back pain—Methotrexate—psoriatic arthritis	0.00059	0.00142	CcSEcCtD
Trametinib—Fatigue—Dexamethasone—psoriatic arthritis	0.00059	0.00142	CcSEcCtD
Trametinib—Fatigue—Betamethasone—psoriatic arthritis	0.00059	0.00142	CcSEcCtD
Trametinib—MAP2K1—Immune System—MEFV—psoriatic arthritis	0.000585	0.00497	CbGpPWpGaD
Trametinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000584	0.00141	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00058	0.00493	CbGpPWpGaD
Trametinib—Skin disorder—Prednisone—psoriatic arthritis	0.000579	0.00139	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000576	0.00139	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—psoriatic arthritis	0.000575	0.00138	CcSEcCtD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000569	0.00483	CbGpPWpGaD
Trametinib—Anaemia—Methotrexate—psoriatic arthritis	0.000564	0.00136	CcSEcCtD
Trametinib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000559	0.00135	CcSEcCtD
Trametinib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000559	0.00135	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—HLA-C—psoriatic arthritis	0.00055	0.00467	CbGpPWpGaD
Trametinib—Leukopenia—Methotrexate—psoriatic arthritis	0.000546	0.00132	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000543	0.00131	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000543	0.00461	CbGpPWpGaD
Trametinib—Dizziness—Prednisolone—psoriatic arthritis	0.000542	0.00131	CcSEcCtD
Trametinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000541	0.0013	CcSEcCtD
Trametinib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000541	0.0013	CcSEcCtD
Trametinib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000541	0.0013	CcSEcCtD
Trametinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000541	0.0013	CcSEcCtD
Trametinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000541	0.0013	CcSEcCtD
Trametinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.00054	0.0013	CcSEcCtD
Trametinib—Insomnia—Prednisone—psoriatic arthritis	0.000539	0.0013	CcSEcCtD
Trametinib—Pruritus—Triamcinolone—psoriatic arthritis	0.000533	0.00128	CcSEcCtD
Trametinib—Cough—Methotrexate—psoriatic arthritis	0.000532	0.00128	CcSEcCtD
Trametinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000532	0.00128	CcSEcCtD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000521	0.00442	CbGpPWpGaD
Trametinib—Arthralgia—Methotrexate—psoriatic arthritis	0.000519	0.00125	CcSEcCtD
Trametinib—Myalgia—Methotrexate—psoriatic arthritis	0.000519	0.00125	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000518	0.00125	CcSEcCtD
Trametinib—Rash—Prednisolone—psoriatic arthritis	0.000517	0.00125	CcSEcCtD
Trametinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000517	0.00124	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000516	0.00124	CcSEcCtD
Trametinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000515	0.00124	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—HLA-C—psoriatic arthritis	0.000515	0.00437	CbGpPWpGaD
Trametinib—Fatigue—Prednisone—psoriatic arthritis	0.000514	0.00124	CcSEcCtD
Trametinib—Headache—Prednisolone—psoriatic arthritis	0.000514	0.00124	CcSEcCtD
Trametinib—Constipation—Prednisone—psoriatic arthritis	0.00051	0.00123	CcSEcCtD
Trametinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000499	0.0012	CcSEcCtD
Trametinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000498	0.0012	CcSEcCtD
Trametinib—Infection—Methotrexate—psoriatic arthritis	0.000495	0.00119	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000491	0.00417	CbGpPWpGaD
Trametinib—Asthenia—Betamethasone—psoriatic arthritis	0.000491	0.00118	CcSEcCtD
Trametinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000491	0.00118	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000488	0.00118	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000488	0.00117	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000487	0.00117	CcSEcCtD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000487	0.00414	CbGpPWpGaD
Trametinib—Nausea—Prednisolone—psoriatic arthritis	0.000487	0.00117	CcSEcCtD
Trametinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000484	0.00117	CcSEcCtD
Trametinib—Pruritus—Betamethasone—psoriatic arthritis	0.000484	0.00117	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000484	0.00116	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000481	0.00116	CcSEcCtD
Trametinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000479	0.00115	CcSEcCtD
Trametinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000478	0.00115	CcSEcCtD
Trametinib—Rash—Triamcinolone—psoriatic arthritis	0.000475	0.00114	CcSEcCtD
Trametinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000475	0.00114	CcSEcCtD
Trametinib—Rash—Methylprednisolone—psoriatic arthritis	0.000474	0.00114	CcSEcCtD
Trametinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000474	0.00114	CcSEcCtD
Trametinib—Headache—Triamcinolone—psoriatic arthritis	0.000472	0.00114	CcSEcCtD
Trametinib—Headache—Methylprednisolone—psoriatic arthritis	0.000471	0.00114	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—psoriatic arthritis	0.000471	0.00113	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000471	0.00113	CcSEcCtD
Trametinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000468	0.00113	CcSEcCtD
Trametinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000468	0.00113	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000459	0.0039	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000454	0.00109	CcSEcCtD
Trametinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000452	0.00109	CcSEcCtD
Trametinib—Dizziness—Betamethasone—psoriatic arthritis	0.000452	0.00109	CcSEcCtD
Trametinib—Insomnia—Methotrexate—psoriatic arthritis	0.00045	0.00108	CcSEcCtD
Trametinib—Nausea—Triamcinolone—psoriatic arthritis	0.000448	0.00108	CcSEcCtD
Trametinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000447	0.00108	CcSEcCtD
Trametinib—Vomiting—Betamethasone—psoriatic arthritis	0.000435	0.00105	CcSEcCtD
Trametinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000435	0.00105	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000433	0.00104	CcSEcCtD
Trametinib—Rash—Betamethasone—psoriatic arthritis	0.000431	0.00104	CcSEcCtD
Trametinib—Rash—Dexamethasone—psoriatic arthritis	0.000431	0.00104	CcSEcCtD
Trametinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000431	0.00104	CcSEcCtD
Trametinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000431	0.00104	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00043	0.00104	CcSEcCtD
Trametinib—Fatigue—Methotrexate—psoriatic arthritis	0.000429	0.00103	CcSEcCtD
Trametinib—Headache—Dexamethasone—psoriatic arthritis	0.000429	0.00103	CcSEcCtD
Trametinib—Headache—Betamethasone—psoriatic arthritis	0.000429	0.00103	CcSEcCtD
Trametinib—Asthenia—Prednisone—psoriatic arthritis	0.000427	0.00103	CcSEcCtD
Trametinib—Pruritus—Prednisone—psoriatic arthritis	0.000422	0.00102	CcSEcCtD
Trametinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000408	0.000982	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000407	0.000981	CcSEcCtD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000406	0.00345	CbGpPWpGaD
Trametinib—Nausea—Betamethasone—psoriatic arthritis	0.000406	0.000979	CcSEcCtD
Trametinib—Nausea—Dexamethasone—psoriatic arthritis	0.000406	0.000979	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—NOD2—psoriatic arthritis	0.000404	0.00344	CbGpPWpGaD
Trametinib—Dizziness—Prednisone—psoriatic arthritis	0.000394	0.000949	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000394	0.000948	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000394	0.000948	CcSEcCtD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.00038	0.00323	CbGpPWpGaD
Trametinib—Vomiting—Prednisone—psoriatic arthritis	0.000379	0.000912	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—NOD2—psoriatic arthritis	0.000378	0.00322	CbGpPWpGaD
Trametinib—Rash—Prednisone—psoriatic arthritis	0.000376	0.000905	CcSEcCtD
Trametinib—Dermatitis—Prednisone—psoriatic arthritis	0.000375	0.000904	CcSEcCtD
Trametinib—Headache—Prednisone—psoriatic arthritis	0.000373	0.000899	CcSEcCtD
Trametinib—Asthenia—Methotrexate—psoriatic arthritis	0.000357	0.00086	CcSEcCtD
Trametinib—Nausea—Prednisone—psoriatic arthritis	0.000354	0.000852	CcSEcCtD
Trametinib—Pruritus—Methotrexate—psoriatic arthritis	0.000352	0.000848	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000349	0.00297	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—REL—psoriatic arthritis	0.000348	0.00296	CbGpPWpGaD
Trametinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000341	0.000821	CcSEcCtD
Trametinib—Dizziness—Methotrexate—psoriatic arthritis	0.000329	0.000793	CcSEcCtD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000327	0.00278	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—REL—psoriatic arthritis	0.000326	0.00277	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HLA-B—psoriatic arthritis	0.000325	0.00276	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-C—psoriatic arthritis	0.00032	0.00272	CbGpPWpGaD
Trametinib—Vomiting—Methotrexate—psoriatic arthritis	0.000317	0.000762	CcSEcCtD
Trametinib—Rash—Methotrexate—psoriatic arthritis	0.000314	0.000756	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000314	0.000755	CcSEcCtD
Trametinib—Headache—Methotrexate—psoriatic arthritis	0.000312	0.000751	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—HLA-B—psoriatic arthritis	0.000304	0.00259	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-C—psoriatic arthritis	0.0003	0.00255	CbGpPWpGaD
Trametinib—Nausea—Methotrexate—psoriatic arthritis	0.000296	0.000712	CcSEcCtD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000295	0.00251	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CRP—psoriatic arthritis	0.000288	0.00244	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CRP—psoriatic arthritis	0.000269	0.00229	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NOD2—psoriatic arthritis	0.000236	0.002	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NOD2—psoriatic arthritis	0.00022	0.00187	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-B—psoriatic arthritis	0.000189	0.00161	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-B—psoriatic arthritis	0.000177	0.00151	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CRP—psoriatic arthritis	0.000167	0.00142	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DRB1—psoriatic arthritis	0.00016	0.00136	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CRP—psoriatic arthritis	0.000157	0.00133	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DRB1—psoriatic arthritis	0.00015	0.00127	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—psoriatic arthritis	0.000147	0.00125	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS2—psoriatic arthritis	0.000141	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—psoriatic arthritis	0.000138	0.00117	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS2—psoriatic arthritis	0.000132	0.00112	CbGpPWpGaD
